JAAHA Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hosoya, K.
Right arrow Articles by Couto, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hosoya, K.
Right arrow Articles by Couto, C. G.
Journal of the American Animal Hospital Association 45:14-18 (2009)
© 2009 American Animal Hospital Association

Retrospective Study

Adjuvant CCNU (Lomustine) and Prednisone Chemotherapy for Dogs With Incompletely Excised Grade 2 Mast Cell Tumors

Kenji Hosoya, DVM, MS, Diplomate ACVR (Radiation Oncology), William C. Kisseberth, DVM, PhD, Diplomate ACVIM (Oncology), Francisco J. Alvarez, DVM, MS, Diplomate ACVIM (Oncology), Ana Lara-Garcia, DVM, MS, PhD, Diplomate ACVIM (Oncology), Gillian Beamer, DVM, PhD, Paul C. Stromberg, DVM, PhD, Diplomate ACVP (Pathology) and C. Guillermo Couto, DVM, Diplomate ACVIM (Oncology, Internal Medicine)

From the Departments of Veterinary Clinical Sciences (Hosoya, Kisseberth, Alvarez, Lara-Garcia, Couto) and Veterinary Biosciences (Beamer, Stromberg), College of Veterinary Medicine, and the Comprehensive Cancer Center (Kisseberth, Couto), The Ohio State University, 601 Vernon L. Tharp Street, Columbus, Ohio 43210.

The use of adjuvant 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; lomustine) to treat incompletely excised canine mast cell tumors (MCTs) has not been evaluated. Medical records of 12 dogs with grade 2 MCT treated with incomplete surgical excision and adjuvant CCNU and prednisone chemotherapy were reviewed. Local recurrence rate, metastasis rate, and survival time were evaluated. None of the dogs developed local recurrence or regional/ distant metastases. Two dogs developed fatal liver failure. The 1- and 2-year progression-free rates of surviving dogs were 100% and 77%, respectively. Postoperative adjuvant CCNU appears to be a useful alternative to radiation therapy for incompletely excised canine cutaneous MCTs.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Animal Hospital Association.